301 related articles for article (PubMed ID: 15581967)
1. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
2. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
3. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
4. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
5. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
8. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
D'Angelo E; Spagnoli LG; Prat J
Hum Pathol; 2009 Nov; 40(11):1571-85. PubMed ID: 19540555
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
Ioffe YJ; Li AJ; Walsh CS; Karlan BY; Leuchter R; Forscher C; Cass I
Gynecol Oncol; 2009 Dec; 115(3):466-71. PubMed ID: 19767065
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in uterine sarcoma.
Gadducci A
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):783-95. PubMed ID: 21764643
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
Amant F; Schurmans K; Steenkiste E; Verbist L; Abeler VM; Tulunay G; De Jonge E; Massuger L; Moerman P; Vergote I
Gynecol Oncol; 2004 Jun; 93(3):680-5. PubMed ID: 15196864
[TBL] [Abstract][Full Text] [Related]
13. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
14. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Matsumoto Y; Ishiko O; Sumi T; Yoshida H; Deguchi M; Nakagawa E; Haba T; Wakasa K; Ogita S; Ando Y
Oncol Rep; 2001; 8(6):1225-7. PubMed ID: 11605037
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.
Coosemans A; Nik SA; Caluwaerts S; Lambin S; Verbist G; Van Bree R; Schelfhout V; de Jonge E; Dalle I; Jacomen G; Cassiman JJ; Moerman P; Vergote I; Amant F
Eur J Cancer; 2007 Jul; 43(10):1630-7. PubMed ID: 17531467
[TBL] [Abstract][Full Text] [Related]
18. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
[TBL] [Abstract][Full Text] [Related]
19. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.
Akahira J; Tokunaga H; Toyoshima M; Takano T; Nagase S; Yoshinaga K; Tase T; Wada Y; Ito K; Niikura H; Yamada H; Sato A; Sasano H; Yaegashi N
Oncology; 2006; 71(5-6):333-40. PubMed ID: 17690557
[TBL] [Abstract][Full Text] [Related]
20. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
